Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007201
Chunk: 113

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 113
---
 Ordinary Shares (in the form of         
 Depositary Shares) and Series K Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 148,930,000 Ordinary  
 Shares (in the form of Depositary Shares) and which we are registering hereby. The warrants are subject to a beneficial ownership limitation  
 of 4.99% or 9.99%, as applicable, which does not permit the selling shareholder to exercise that portion of the warrants that would result    
 in the selling shareholder and its affiliates owning, after exercise, a number of our Ordinary Shares in excess of the beneficial ownership   
 limitation. The amounts and percentages in the table do not give effect to the 4.99% or 9.99% beneficial ownership limitation, if applicable. 
 Iroquois Capital Management L.L.C. is the investment manager of Iroquois Master Fund, Ltd. Iroquois Capital Management, LLC has voting        
 control and investment discretion over securities held by Iroquois Master Fund. As Managing Members of Iroquois Capital Management, LLC,      
 Richard Abbe and Kimberly Page make voting and investment decisions on behalf of Iroquois Capital Management, LLC in its capacity as          
 investment manager to Iroquois Master Fund Ltd. As a result of the foregoing, Mr. Abbe and Mrs. Page may be deemed to have beneficial         
 ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the securities held by Iroquois Capital   
 Management and Iroquois Master Fund. The principal business address of Iroquois Master Fund Ltd. is c/o Iroquois Capital Management,          
 LLC, 2 Overhill Road, Suite 400, Scarsdale, NY 10583.                                                                                         |

| (8) | The selling                                                                                                                                   
 shareholder holds (i) warrants issued by us in prior transactions which entitle the selling shareholder                                       
 to purchase an aggregate of 309,660,000 Ordinary Shares (in the form of Depositary Shares), and (ii) Series                                   
 J Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 425,530,000 Ordinary Shares (in the form of         
 Depositary Shares) and Series K Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 425,530,000 Ordinary  
 Shares (in the form of Depositary Shares) and which we are registering hereby. The